Back to IIDMM

Recent Publications

  1. Riou C, Treurnicht F, Abrahams M-R, Mlisana K, Liu MKP, Goonetilleke N, Koup R, Roederer M, Karim S.A, De Bruyn G, Williamson C, Gray CM, Burgers WA. Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8 + T cells. Journal of Immunology (2012) 189(8):3838-3847.
  2. Musyoki A, Mothapo K, Rakgole J, Lukhwareni A, Bessong P, Selabe G, Bredell H, Williamson C, Mphahlele MJ. Genetic characterization of HIV before widespread testing of HIV vaccine candidates at a clinical trial site in Pretoria, South Africa.
    AIDS Research and Human Retroviruses (2012) 28 (9):1131-1138. 
  3. Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, Arney L, Naranbhai V, Treurnicht F, Abrahams M-R, Bandawe G, Swanstrom R, Karim QA, Karim SSA, Williamson C. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
    Journal of Infectious Diseases (2012) 206(1):35-40.
  4. Sheward DJ, Murrell B, Williamson C. Degenerate Primer IDs and the birthday problem.
    Proceedings of the National Academy of Sciences of the USA  (2012) 109(21):E1330.
  5. Williamson A-L, Rybicki E, Shephard E, Gray G, Bekker L-G, Downing K, Williamson C. South African HIV-1 vaccine candidates - the journey from the bench to clinical trials.
    South African Medical Journal (2012) 102(6):452-455.
  6. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams M-R, Lambson BE, Ranchobe N, Ping L, Ngandu N, Karim QA, Karim SSA, Swanstrom RI, Seaman MS, Williamson C, Morris L. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.
    Nature Medicine (2012) 18(11):1688-1692.
  7. Roberts L, Passmore JA, Mlisana K, Williamson C, Little F, Bebell LM, Walzl G, Abrahams MR, Woodman Z, Abdool Karim Q, Abdool Karim SS. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women.
    Journal of Infectious Diseases (2012) 205(2):194-203.
  8. Mlisana K, Naicker N, Werner L, Roberts L, van Loggerenberg F, Baxter C, Passmore JS, Grobler AC, Sturm AW, Williamson C, Ronacher K, Walzl G and Abdool Karim SS. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa.
    Journal of Infectious Diseases (2012) 206:6-14.
  9. Liu MK, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, Li H, Pavlicek JW, Cai F, Rose-Abrahams M, Treurnicht F, Hraber P, Riou C, Gray C, Ferrari G, Tanner R, Ping LH, Anderson JA, Swanstrom R, Cohen M, Karim SS, Haynes B, Borrow P, Perelson AS, Shaw GM, Hahn BH, Williamson C, Korber BT, Gao F, Self S, McMichael A, Goonetilleke N. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape.
    Journal of Clinical Investigation (2012) 123(1):380-93.
  10. Chopera DR, Cotton LA, Zawaira A, Mann JK, Ngandu NK, Ntale R, Carlson JM, Mlisana K, Woodman Z, de Assis Rosa D, Martin E, Miura T, Pereyra F, Walker BD, Gray CM, Martin DP, Ndung'u T, Brockman MA, Abdool Karim S, Brumme ZL, Williamson C; the CAPRISA 002 Study Team. Intersubtype differences in the effect of a rare p24 Gag mutation on HIV-1 replicative fitness.
    Journal of Virology (2012) 86(24):13423-33.
  11. Ntale RS, Chopera DR, Ngandu NK, Assis de Rosa D, Zembe L, Gamieldien H, Mlotshwa M, Werner L, Woodman Z, Mlisana K, Abdool Karim S, Gray CM, Williamson C; the CAPRISA 002 Study Team. Temporal association of HLA-B*81:01 and B*39:10 mediated HIV-1 p24 sequence evolution with disease progression.
    Journal of Virology (2012) 86(22):12013-24.
  12. Shen YJ, Shephard E, Douglass N, Johnston N, Adams C, Williamson C, Williamson AL. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
    Virol J. 2011 May 30;8:265.
  13. Chopera D.R., Mlotshwa M., Woodman Z., Mlisana K., de Assis Rosa D, Martin D.P., Abdool Karim S., Gray C.M., Williamson C. and the CAPRISA 002 Study Team. Virological and Immunological Factors Associated with HIV-1 Differential Disease Progression in HLA-B*58:01 Positive Individuals.
    J. Virol. 2011 Jul;85(14):7070-7080. Epub 2011 May.
  14. Hemelaar J, Gouws E, Ghys PD, Osmanov S, & WHO-UNAIDS Network for HIV Isolation and Characterisation (including Williamson C.). Global trends in molecular epidemiology of HIV-1 during 2000-2007.
    AIDS, 2011 25(5):679-89.
  15. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; and the CAPRISA 002 Study. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop.
    J Virol. 2011 Apr;85(7):3128-41.
  16. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L; the CAPRISA 002 study team. HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection.
    J Virol. 2011 Mar 9. [Epub ahead of print]
  17. Ssemwanga D, Lyagoba F, Ndembi N, Mayanga BN, Larke N, Wang S, Baalwa J, Williamson C, Grosskurth H, Kaleebu P. Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda.
    Virology J. 2011 March 01; 411(1): 113-131.
  18. Woodman Z, Mlisana K, Treurnicht F, Abrahams M-R, Thebus R, Abdool-Karim S and Williamson C for the CAPRISA Acute Infection Study Team. Decreased Incidence of Dual Infections in South African Subtype C-Infected Women Compared to a Cohort Ten Years Earlier. AIDS Research and Human Retroviruses, 2011 Feb 9. [Epub ahead of print]
  19. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L and the CAPRISA 002 study team. HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection.
    J. Virol. 2011, 10.1128/JVI.00198-11
  20. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, and Morris L and the CAPRISA 002 study. Potent and broad neutralization of HIV-1 subtype C viruses by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.
    J Virol 2011 Apr;85(7):3128-41. Epub 2011 Jan 26.
  21. Nofemela A, Bandawe G, Thebus R, Marais J, Natasha Wood N, Maboko L, Hoelscher M, Woodman Z, Williamson C. Defining the HIV-1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant forms.
    Virology 2011 Jul 5;415(2):107-13. Epub 2011 May 4.
  22. Mlotshwa M., Riou C., Chopera D., de Assis Rosa D., Ntale R, lorette Treunicht F, Woodman Z, Werner L, van Loggerenberg F., Mlisana K, Salim Abdool Karim S., Williamson C, Gray C.M., the CAPRISA 002 Study Team Fluidity of HIV-1-Specific T-Cell Responses during Acute and Early Subtype C HIV-1 Infection and Associations with Early Disease Progression.
    J Virol, Nov. 2010; 84:12018-12029.
  23. Mosha F, Urassa W, Aboud S, Lyamuya E, Sandstrom E, Bredell H, Williamson C. Prevalence of Genotypic Resistance to Antiretroviral Drugs in Treatment-Naive Youths Infected with Diverse HIV Type 1 Subtypes and Recombinant Forms in Dar es Salaam, Tanzania.  AIDS Res Hum Retroviruses. 2011 Apr;27(4):377-82. Epub 2010 Oct 18
  24. Saathoff E, Pritsch M, Geldmacher C, Hoffmann O, Koehler R N, Maboko , L, Maganga L, Geis S, McCutchan FE, Kijak GH, Kim JH,  Arroyo MA,  Gerhardt M, Tovanabutra S, Robb ML, Williamson C, Michael NL, Hoelscher M.  Viral and Host Factors Associated With the HIV-1 Viral Load Setpoint in Adults From Mbeya Region, Tanzania. 
    JAIDS Journal of Acquired Immune Deficiency Syndromes.     54(3):324-331, July 1, 2010
  25. Roberts L, Passmore JA, Williamson C, Little F, Bebell LM, Mlisana K, Burgers WA, van Loggerenberg F, Walzl G, Djoba Siawaya JF, Abdool Karim Q, Abdool Karim SS. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression.
    AIDS    . 2010 Mar 27;24(6):819-31.PMID: 20224308 PMID: 20224308
  26. Kraus MH, Parrish NF, Shaw KS, Decker JM, Keele BF, Salazar-Gonzalez JF, Grayson T, McPherson DT, Ping L-H, Anderson JA, Swanstrom R, Williamson C, Shaw GM, Beatrice H. Hahn BH. A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. 
    Virology. 2010. Feb 20;397(2):346-57. PMID: 20003995
  27. Treurnicht F.K, Seoighe C. Martin DP, Wood N, Abrahams M-R, de Assis Rosa D, Bredell H, Woodman Z, Hide W, Mlisana K, Abdool Karim S, Williamson C. Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure.
    Virology.     2010 Jan 20;396(2):213-25.
  28. Moore PL, Ranchobe N, Lambson BE, Gray ES,  Cave E, Abrahams MR, Bandawe G , Mlisana K, Abdool Karim SS, Williamson C and Morris L, the CAPRISA 002 study and the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection.
    Plos Pathogens. 2009. Sept 5(9)  e1000598.
  29. Morris L, Williamson C, Mlisana K and Gray G. Where are we going with HIV vaccines?
    South African Journal of Science 2009 105, 2009:1-2.
  30. Woodman Z and Williamson C. HIV molecular epidemiology: transmission and adaptation to human populations.
    Current Opinion in HIV and AIDS 2009, 4:247-252
  31. Burgers WA, Riou C, Mlotshwa M, Maenetje P, de Assis Rosa D, Brenchley J, Mlisana K, Douek DC, Koup R, Roederer M, de Bruyn G, Karim SA, Williamson C, Gray CM; and the CAPRISA 002 Acute Infection Study Team. Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point.
    J Immunol.     2009 Apr 15;182(8):4751-61
  32. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS, Treurnicht FK, Keele BF, Wood N, Salazar-Gonzalez JF, Bhattacharya T, Chu H, Hoffman I, Galvin S, Mapanje C, Kazembe P, Thebus R, Fiscus S, Hide W, Cohen MS, Karim SA, Haynes BF, Shaw GM, Hahn BH, Korber BT, Swanstrom R, Williamson C; Quantitating the multiplicity of infection with HIV-1 subtype C reveals a non-Poisson distribution of transmitted variants.  for the CAPRISA Acute Infection Study Team and the Center for HIV-AIDS Vaccine Immunology Consortium.
    J Virol.     2009 Feb 4.
  33. Burgers WA, Chege GK, Müller TL, van Harmelen JH, Khoury G, Shephard EG, Gray CM, Williamson C, Williamson AL Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons.
    J Gen Virol. 2009 Feb;90(Pt 2):468-80
  34. Bandawe GP, Martin DP, Treurnicht F, Mlisana K, Abdool Karim SS, Williamson C, Caprisa 002 Acute Infection Study Team T.Conserved positive selection signals in HIV-1 gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection.
    Virol J    . 2008 Nov 24;5(1):141.
  35. Gray CM, Mlotshwa M, Riou C, Mathebula T, de Assis Rosa D, Mashishi T, Seoighe C, Ngandu N, van Loggerenberg F, Morris L, Mlisana K, Williamson C, Karim SA; on behalf of the CAPRISA 002 Acute Infection Study Team. HIV-specific IFN{gamma}-ELISPOT Responses targeting specific regions of the proteome during Primary Subtype C Infection are poor Predictors of the Course of Viraemia and Set Point.
    J Virol. 2009 Jan;83(1):470-8. Epub 2008 Oct.22
  36. Kaleebu P, Abimiku A, El-Halabi S, Koulla-Shiro S, Mamotte N, Mboup S, Mugerwa R, Nkengasong J, Toure-Kane C, Tucker T, Wassenaar D, Williamson C, Wolday D. African AIDS Vaccine Programme for a Coordinated and Collaborative Vaccine Development Effort on the Continent.
    PLoS Medicine     2008 Dec: 5(12).
  37. Beck I.A., Crowell C, Kittoe R, Bredell H, Machaba M, Willamson C, Janssens W, Jallow S, van der Groen G, Shao Y, Jacob M, Samuel NM, Lorenzana de Rivera I, Ngo-Giang-Huong N, Cassol S, Alemnji G, and Frenkel L.M. Optimization of the Oligonucleotide Ligation Assay (OLA), a Rapid and Inexpensive Test for Detection of HIV-1 Drug-Resistance Mutations, for Non-North American Variants.
    Journal of Acquired Immune Deficiency Syndromes.     2008 Aug 1;48(4):418-27.
  38. van Loggerenberg F, Mlisana K, Williamson C, Auld S.C., Morris L, Gray C.M., Abdool Karim Q, Grobler A,  Barnabas N, Iriogbe I, Abdool Karim S.S. for the CAPRISA 002 Acute Infection Study Team. Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study.
    Plos One 2008 Apr: 3(4).
  39. Chege, G. K., E. G. Shephard, A. Meyers, H. J. van, C. Williamson, A. Lynch, C. M. Gray, E. P. Rybicki, and A. L. Williamson. 2008. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine.
    J. Gen. Virol. 89:2214-2227.
  40. Bebell LM, Passmore J-A, Williamson C, Mlisana K, Iriogbe I, van Loggerenberg F, Abdool Karim Q, Abdool Karim S.  Relationship between Levels of Inflammatory Cytokines in the Genital Tract and CD4(+) Cell Counts in Women with Acute HIV-1 Infection.
    Journal of Infectious Diseases 2008  Sep 1;198(5):710-714.
  41. Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, Seoighe C, Treurnicht F, Assis de Rosa D, Hide W, Abdool Karim S, Gray CM, Williamson C, and the CAPRISA 002 study team. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.
    PLoS Pathogens 2008 Mar: 4(3). e1000033.
  42. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, Williamson C, Morris L, CAPRISA 002 Study Team. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.
    J Virol    . 2008 Feb;82(4):1860-9.
  43. Burgers WA, Shephard E, Monroe JE, Greenhalgh T, Binder A, Hurter E, Van Harmelen JH, Williamson C, Williamson AL. Construction, Characterization, and Immunogenicity of a Multigene Modified Vacinia Ankara (MVA) Vaccine Based on HIV Type 1 Subtype C.
    AIDS Res Hum Retroviruses. 2008 Feb;24(2):195-206.
  44. Shephard E, Burgers WA, Van Harmelen JH, Monroe JE, Greenhalgh T, Williamson C, Williamson AL. A Multigene HIV Type 1 Subtype C Modified Vaccinia Ankara (MVA) Vaccine Efficiently Boosts Immune Responses to a DNA Vaccine in Mice.
    AIDS Res Hum Retroviruses    . 2008 Feb;24(2);207-217. PMID: 18240963
  45. Milsana, K, Auld SC, Grobler A, Loggerenberg F, Williamson C, Iriogbe I, Sobieszcyk ME, Abdool Karim SS; for the CAPRISA Acute Infection Study Team. Anaemia in Acute HIV-1 Subtype C Infection.
    PLoS One. 2008 Feb;3(2):e1626.

 

  DGWUCTIIDMM